Corrigendum



Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – CORRIGENDUM

Colleen Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B. Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew A. Somogyi, Kyle Lapidus, Elizabeth Stratton, Kirsten Gainsford, Deepak Garg, Nicollette L. R. Thornton, Célia Fourrier, Karyn Richardson, Demi Rozakis, Anish Scaria, Cathrine Mihalopoulos, Mary Lou Chatterton, William M. McDonald, Philip Boyce, Paul E. Holtzheimer, F. Andrew Kozel, Patricio Riva-Posse and Anthony Rodgers

Copyright and usage

© The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative

Doi: 10.1192/bjp.2023.79, Published online by Cambridge University Press 14 July 2023

This article was originally published with an error in the outcome of blinding assessment results. The paper reported outcomes for the evaluation of blinding at the end of the 4-week RCT, but the data used was from the evaluation done after treatment one, rather than the end of RCT timepoint.

The errors have been rectified in the online versions of the article and linked supplementary material.

Colleen Loo; Nick Glozier; David Barton; Bernhard T. Baune; Natalie T. Mills; Paul Fitzgerald; Paul Glue; Shanthi Sarma; Veronica Galvez-Ortiz; Dusan Hadzi-Pavlovic; Angelo Alonzo; Vanessa Dong; Donel Martin; Stevan Nikolin; Philip B. Mitchell; Michael Berk; Gregory Carter; Maree Hackett; John Leyden; Sean Hood; Andrew A. Somogyi; Kyle Lapidus; Elizabeth Stratton; Commons Attribution licence (https://creativecommons.org/ licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kirsten Gainsford; Deepak Garg; Nicollette L. R. Thornton; Célia Fourrier; Karyn Richardson; Demi Rozakis; Anish Scaria; Cathrine Mihalopoulos; Mary Lou Chatterton; William M. McDonald; Philip Boyce; Paul E. Holtzheimer; F. Andrew Kozel; Patricio Riva-Posse; Anthony Rodgers

Reference

Loo C, Glozier N, Barton D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. *The British Journal of Psychiatry*. 2023;**223**(6):533–541.

